ALX Oncology (ALXO) Stock Price, News & Analysis

Company Overview

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.45 to $0.47
• 50-Day Range: $0.41 to $0.58
• 52-Week Range: $0.40 to $8.78
• Volume: 235,616 shs
• Average Volume: 932,115 shs
• Market Capitalization: $25.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.30
• Consensus Rating: Moderate Buy

ALX Oncology Stock Analysis - MarketRank™

ALX Oncology scored higher than 53% of companies evaluated by MarketBeat, and ranked 1468th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

ALX Oncology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ALX Oncology are expected to grow in the coming year, from ($2.76) to ($2.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ALX Oncology is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ALX Oncology is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ALX Oncology has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.09% of the float of ALX Oncology has been sold short.

Short Interest Ratio / Days to Cover

ALX Oncology has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.

Change versus previous month

Short interest in ALX Oncology has recently decreased by 4.39%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ALX Oncology does not currently pay a dividend.

Dividend Growth

ALX Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.09% of the float of ALX Oncology has been sold short.

Short Interest Ratio / Days to Cover

ALX Oncology has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.

Change versus previous month

Short interest in ALX Oncology has recently decreased by 4.39%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

ALX Oncology has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ALX Oncology this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ALXO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ALX Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $659.00 in company stock.

Percentage Held by Insiders

21.00% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALXO Stock Analysis - Frequently Asked Questions

How have ALXO shares performed this year?

ALX Oncology's stock was trading at $1.67 at the beginning of the year. Since then, ALXO stock has decreased by 71.9% and is now trading at $0.47.

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.11.

When did ALX Oncology IPO?

ALX Oncology (ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at a price of $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager.

How do I buy shares of ALX Oncology?

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ALX Oncology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALXO
• CIK: 1810182
• Web: www.alxoncology.com
• Phone: 650-466-7125
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.30
• High Stock Price Target: $9.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +602.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$134.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -104.43%
• Return on Assets: -77.74%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 5.47
• Quick Ratio: 5.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.14 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 53,400,000
• Free Float: 42,183,000
• Market Cap: $25.10 million
• Optionable: Optionable
• Beta: 1.11